Trials / Completed
CompletedNCT01709110
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,366 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teriparatide | Administered SC |
| DRUG | Risedronate | Administered orally |
| DRUG | Placebo | Teriparatide arm placebo administered orally. Risedronate arm placebo administered SC. |
| DRUG | Calcium | Administered orally |
| DRUG | Vitamin D | Administered orally |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2012-10-17
- Last updated
- 2019-09-23
- Results posted
- 2018-01-23
Locations
103 sites across 15 countries: United States, Argentina, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Puerto Rico, Spain
Source: ClinicalTrials.gov record NCT01709110. Inclusion in this directory is not an endorsement.